Use of Post-transplant Cyclophosphamide (PTCy) has recently been introduced specifically in the haplo-identical transplant setting with promising results [1] . This intervention has also shown a significant reduction of acute graft versus host disease (aGVHD) and a trend towards improving chronic graft versus host disease (cGVHD) [2] . The efficacy of PTCy has mainly been demonstrated in patients with bone marrow (BM) as the stem cell source [3] ; and has been associated with clinically significant acute and chronic GVHD in patients with peripheral blood as the stem cell source (PBSC) [4] . Anti-thymocyte globulin (ATG) has previously been shown to reduce the incidence of cGVHD at around 1 year post transplantation [5] , without increasing the incidence of relapse [6] . The incidence of Gr III-IV aGVHD was 28% using ATG, cyclosporine and mycophenolate mofetil (ATG-CSA-MF), as the GVHD prophylaxis regimen, in the recently concluded randomized trial [7] . We hypothesized that a combination of both ATG and PTCy would reduce the incidence of both acute and chronic GVHD in our patient cohort; effectively reducing the morbidity and mortality associated with severe forms of GVHD. Here we present the preliminary outcome in our unrelated patients using this regimen. This is a retrospective study of the patient cohort treated from 1 October 2015 until 31 March 2016 in a single center. This study was approved by the institutional Research Ethics Board. This study cohort was compared to the earlier historical study cohort of patients who received pre transplant ATG as part of GVHD prophylaxis at our center [7] . Patients received transplant from HLA-Matched (10/10) or mismatched (9/10) unrelated donors. The graft source was Filgrastim stimulated PBSC. The treatment schema initially for ages <60 years was a myeloablative regimen using the FBT400 protocol and for ages >60 years consisted of FBT200 as the reduced intensity conditioning (RIC) regimen [8] . The FBT400 regimen consisted of a combination of Fludarabine (50 mg/m2 on days −5,−4,−3,−2), Busulphan (once daily dose of 3.2 mg/kg on days −5,−4,−3,−2) along with 2 doses of total body irradiation (TBI) of 200 cGy on Day −1. The regimen of FBT200 comprised of reduced dose of Fludarabine at 30 mg/m2 on same days but with only 2 days of Busulphan (on days −2,−1) and only one dose of 200 cGy TBI on day −1 [9] . We subsequently decided to use FBT200 for all patients in view of increased liver and kidney toxicities observed with FBT400 regimen with post-transplant cyclophosphamide. The GVHD prophylaxis consisted of ATG (rabbit, Thymoglobulin; Genzyme-Sanofi, Lyon, France) on days −3, −2 and −1 with a total dose of 4.5 mg/kg. Patients additionally received 50 mg/kg/day IV cyclophosphamide on days +3 and +4 (PTCy), with the first dose starting 72 h after PBSC infusion. This was further followed by post transplant administration of IV cyclosporine (2.5 mg/kg twice daily) on day + 5 onwards, with change to oral route when the patient was able to tolerate orally. The median duration for neutrophil engraftment was 18 days (range −13-45 days) and median platelet engraftment was 22 days (range −11-59 days). Table 1A and  Table 1B shows the outcome data for these patients, 75% patients experienced bacterial infections, CMV reactivations was seen in 64% and EBV reactivations in 21% of patients. We observed a significant increase in sinusoidal obstruction syndrome (SOS) between those using FBT 400 in comparison to FBT 200 (54 vs. 17%; p = 0.0412). The odds of having SOS when on FBT 400 is 5.6 times that of being on FBT 200 (95% CI of OR 1.0013-31.3189), in combination with PTCy.
Out of a total of 28 patients, aGVHD was observed in 5 patients, three of whom had overall Grade I-II and two had Grade III. All of these patients responded rapidly to steroids with none showing steroid refractoriness. The cumulative incidence of aGVHD was 17% and Severe Gr III-IV aGVHD was only 7%. Secondary graft failure was seen in 10% of cases. Disease relapse was seen in 4 patients (14.2%), three of whom had minimal residual disease prior to transplantation and received FBT200 conditioning regimen. The OS rate at 1 year was 56% and RFS rate at 1 year was 53%. FBT 200 was associated with significantly better survival as compared to the FBT 400 regimen (76 vs. 36%, p = 0.0095). We compared our novel GVHD prophylaxis regimen (ATG-PTCy-CSA) with our 27 historical cohort patients using ATG-CSA-MF which was instituted at our centre as part of a clinical trial between Jan 2011 and April 2013 Figs. 1a, b] . There were five patients with steroid refractory aGVHD (SR-GVHD) in the ATG-CSA-MF cohort and none in the current GVHD prophylaxis cohort. In the historical cohort, the main cause of death in 7 out of 11 patients was severe aGVHD as compared to none in the ATG-PTCy-CSA cohort. However, there was significant conditioning related toxicity such as pulmonary hemorrhage, sinusoidal obstruction syndrome and bacterial sepsis mainly related to FBT 400 conditioning in the ATGPTCy-CSA regimen, which was not observed in FBT 200 cohort. There was no sufficient evidence of a significant difference between preference of GVHD prophylaxis on overall survival distribution using log-rank test (p-value = 0.5835). There was also no sufficient evidence of a significant difference between preference of GVHD prophylaxis on relapse free survival (p-value = 0.4490). However, there was significant improvement in overall survival in FBT 200 cohort compared to FBT 400 cohort (76 vs. 36%, p = 0.0095) [Fig. 1c] .
Our study is unique in the sense that both anti-T cell agents, i.e., pretransplant ATG and post-transplant PTCy were used, with an aim to reduce both forms of GVHD, which we believe has been done for the first time in hematological malignancies. There is a possibility that in spite of slow T cell depletion of the donor T cells by pre transplant administration of ATG, T cells of the donor escape inhibition leading to manifestations of aGVHD. These escaped T cells when exposed to recipient antigens, exponentially expand to give rise to acute GVHD. Use of Cyclophosphamide on the days of maximum T cell expansion (i.e., days +3 and +4) leads to partial depletion of T cells and leaves T regs behind, leading to amelioration of acute component of GVHD. Cyclophosphamide is not a pan-T cell inhibitor but rather selectively depletes T cells with lower expression of Aldehyde Dehydrogenase. Most of the data on PTCy is extrapolated from haplo-identical transplant where bone marrow is used as a source of stem cells. A higher rate of cGVHD has been reported in the haplo-identical transplant settings using PBSC as graft source with PTCy as prophylaxis [10] . Our hypothesis was that with addition of pre transplant ATG and post transplant CSA, the incidence of both acute and cGVHD will be less in spite of PBSC as the stem cell source [4, 11] . One of the characteristics of the PTCy studies have been a significant lower incidence of EBV reactivations and absence of Post-transplant Lymphoproliferative disorder (PTLD) [12] . Though we observed EBV reactivation in 21%, it was substantially less as compared to other studies using ATG [7] . We are continuing to monitor patients for EBV reactivations and development of PTLD. In haploidentical transplant, there is a concern about increased relapse risk, while using RIC with PTCy and using BM as the stem cell source. We did not observe an increased relapse rate and in our cohort three out of four patients, who had a relapse had persistent minimal residual disease at the time of transplant. We think that stringent disease control may be a prerequisite for the success of this protocol.
Our study is limited by the fact that the number of patients which has been followed up for more than 1 year using this novel protocol is low. However, in comparison to the historical cohort of ATG-CSA-MF, with same supportive care over the years, we were able to demonstrate the effectiveness of combination of ATG and PTCy. The uniqueness of this study reflects in the reduction of both severe and steroid refractory aGVHD using a PBSC graft in patients with hematological malignancies.
In conclusion, the combination of ATG-PTCy-CSA is an effective strategy to reduce aGVHD; especially severe Grade III-IV and significantly decreased the risk of SR-GVHD in unrelated donor transplants. Encouraged by this approach, we are now exclusively treating patients at our center with RIC FBT200 conditioning regimen and with ATG-PTCy-CSA as GVHD prophylaxis. However, more patients need to be followed up to ascertain statistically significant difference. Similarly, longer follow up is needed to evaluate the longitudinal impact of relapses and incidence of cGVHD in our patient population. As PTCy is a promising strategy for GVHD prophylaxis, its combination use with ATG requires further study through randomized clinical trials.
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